Hutchison China MediTech Announces Licensing Agreement with GlaxoSmithKline for KRAS-EGFR Antibody-Drug Conjugate
September 3, 2026 — 23:41 CST
This Data Is Locked!
This area is available only to Subscribers.
Hutchison China MediTech, also known as HUTCHMED, has disclosed an exclusive development and licensing agreement with a subsidiary of GlaxoSmithKline, granting the GSK subsidiary global... [DATA LOCKED]
UNLOCK DATA
Follow the Money & Subscribe for Access to the Best Data and Intelligence on Chinese Venture Capital Deals
